In preclinical models, MEDI2228 effectively killed the majority of MM cell lines and primary MM cells from relapsed/refractory patients, also in the presence of BMSCs or high levels of soluble BCMA. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.